During the last session, Procept BioRobotics Corp (NASDAQ:PRCT)’s traded shares were 1.34 million, with the beta value of the company hitting 1.04. At the end of the trading day, the stock’s price was $63.37, reflecting an intraday loss of -2.48% or -$1.61. The 52-week high for the PRCT share is $103.81, that puts it down -63.82 from that peak though still a striking 28.1% gain since the share price plummeted to a 52-week low of $45.56. The company’s market capitalization is $3.47B, and the average trade volume was 829.88K shares over the past three months.
Procept BioRobotics Corp (PRCT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.36. PRCT has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.49.
Procept BioRobotics Corp (NASDAQ:PRCT) trade information
Procept BioRobotics Corp (PRCT) registered a -2.48% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.48% in intraday trading to $63.37, hitting a weekly high. The stock’s 5-day price performance is -6.96%, and it has moved by -11.06% in 30 days. Based on these gigs, the overall price performance for the year is 29.17%.
The consensus price target of analysts on Wall Street is $105, which implies an increase of 39.65% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $105 and $105 respectively. As a result, PRCT is trading at a discount of -65.69% off the target high and -65.69% off the low.
Procept BioRobotics Corp (PRCT) estimates and forecasts
In the rating firms’ projections, revenue will increase 43.29% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 65.4M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 76.4M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 44.54M and 53.35M respectively. In this case, analysts expect current quarter sales to grow by 46.85% and then jump by 43.21% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.56%. While earnings are projected to return 13.70% in 2025, the next five years will return 37.06% per annum.
PRCT Dividends
Procept BioRobotics Corp is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 4.71 million shares, is of VANGUARD GROUP INC’s that is approximately 9.2375% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $287.87 million.
Also, the Mutual Funds coming in first place with the largest holdings of Procept BioRobotics Corp (PRCT) shares are Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.56 shares. This amounts to just over 2.85 percent of the company’s overall shares, with a $99.14 million market value. The same data shows that the other fund manager holds slightly less at 1.33, or about 2.42% of the stock, which is worth about $84.0 million.
